Skip to content

ondansetron in the treatment of obsessive-compulsive disorder

ondansetron as adjuvant therapy in the treatment of OCD: a double blind randomized trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201204271556N41
Enrollment
40
Registered
2012-04-28
Start date
2012-04-29
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Tablet fluvoxamine (100 mg/day) combined with 8 mg/day of Tablets ondansetron as intervention group for 8 weeks. Intervention 2: Tablet fluvoxamine (100 mg/day) combined with placebo a
Treatment - Drugs
Placebo
Tablet fluvoxamine (100 mg/day) combined with 8 mg/day of Tablets ondansetron as intervention group for 8 weeks

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1-Age between 18-60, 2-Diagnosis of OCD based on DSM IV 3 , Minimum Score of 21 on YALE-BROWN Obsessive-Compulsive Scale- Exclusion Criteria:1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious cardiac, renal or hepatic disease ,5- receiving psychotropic medications during the last 6 weeks 6- pregnancy orbreast feeding 7-rising liver transaminases to three times the upper limit of normal or highe

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of symptoms of OCD. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Y_BOCS( Yale-Brown obsessive compulsive scale).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026